CD8A and neoplasm: One study observed a temporary increase in the number of tumor-specific CD8+ T cells 5 to 8 days after SBRT treatment in patients with non-small cell lung cancer, with inhibitory regulatory T cells (Treg cells) dominating for the next 10 to 16 days.